- Panel favors additional dose for recipients 18 and older
- Seen as convenient, J&J’s shot still used less than others
Johnson & Johnson’s Covid vaccine booster gained a key recommendation from advisers to U.S. regulators that brings the additional shot a step closer to clearance.
The Food and Drug Administration’s vaccine advisory group voted unanimously Friday in favor of recommending the booster for people 18 and older who received their initial immunization at least two months earlier. The experts also indicated support for mixing and matching booster shots from different manufacturers, but didn’t vote on a recommendation.
FDA’s Vaccine and Related Biological Products Advisory Committee voted to back Moderna Inc.’s booster Thursday, and additional shots from the partnership of Pfizer Inc. and BioNTech SE were authorized in September with the panel’s support. While President Joe Biden had foreseen offering boosters to all vaccinated Americans eight months after their first dose, the panel had until now recommended them for people at least 65 years old and younger adults who risk severe illness or viral exposure at work.